Seeking AlphaTue, 14 Apr 2026 11:11:50 GMTEvommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention TranscriptEVMN+2.64%
The Motley FoolTue, 10 Mar 2026 13:51:00 GMT1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next DecadeEVMN+2.64%